Fundz

Theriva Biologics

Rockville, Maryland, United States · Biopharma, Biotechnology, Health Care · 22 employees

Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc. Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. Ramon Alemany, recognized world-wide as a key opinion leader in adenovirus technolo

Funding history

  • Funding Round — $13.1M — Oct 2025
  • Funding Round — $4.0M — Oct 2025
  • Series seed — $3.0M — Aug 2022
  • Series seed — $1.5M — Mar 2022
  • Funding Round — $12.0M — Sep 2017

Recent signals

  • Dec 29, 2025: SEC 8-K (7.01): On December 29, 2025, Theriva Biologics, Inc. announced via a press release that it received Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This advice pertains to the design of a Phase 3 clinical trial for their lead candidate, VCN-01, in combination with gemcitabine/nab-paclitaxel standard-of-care chemotherapy for treating metastatic pancreatic adenocarcinoma. This follows earlier positive results from the VIRAGE Phase 2b clinical trial, which indicated that patients receiving the combination therapy exhibited significantly better survival outcomes compared to those receiving standard treatment. This endorsement from the EMA is critical for the company's ongoing clinical development strategy and may enhance their pathway toward regulatory approval.
  • Oct 24, 2025: Raised $13.1M
  • Oct 24, 2025: SEC 8-K (1.01): On October 24, 2025, Theriva Biologics, Inc. entered into an Amended and Restated At Market Issuance Sales Agreement with A.G.P./Alliance Global Partners to offer and sell up to $4,019,597 of shares of common stock. This agreement allows the company to sell shares through or directly to the Sales Agent over time. The agreement was originally established on February 9, 2021, and has been amended multiple times before this filing. The sale of the shares may have significant financial implications for the company, providing additional capital.
  • Oct 16, 2025: Raised $4.0M
  • Aug 04, 2022: Raised $3.0M in Series seed
  • Mar 21, 2022: Raised $1.5M in Series seed
  • Sep 13, 2017: Raised $12.0M

See plans & pricing → Track Theriva Biologics’s funding, hiring, and signals — with verified contacts — on Fundz.